Drugs in development could result in better hepatitis C treatment

07/21/2010 | New York Times (tiered subscription model), The

About two dozen pharmaceutical firms are pursuing medicines for hepatitis C that could make treatment far more effective and less taxing. The drugs, including Vertex Pharmaceuticals' telaprevir and Merck & Co.'s boceprevir, could give hope to an estimated 300,000 hepatitis C patients who have not responded to existing treatment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC